We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-34.3%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$115M
AUM Growth
+$792K
Cap. Flow
+$6.43M
Cap. Flow %
5.6%
Top 10 Hldgs %
83.12%
Holding
142
New
32
Increased
15
Reduced
32
Closed
53

Top Buys

Rank Stock Value
1
RCON icon
Recon Technology
RCON
+$5M
2
GMVD
G Medical Innovations Holdings Ltd. Ordinary Shares
GMVD
+$3.87M
3
BETS
Bit Brother Limited Class A Ordinary Shares
BETS
+$2.24M
4
CNEY icon
CN Energy Group
CNEY
+$2.19M
5
NMTR
9 Meters Biopharma
NMTR
+$2.08M

Top Sells

Rank Stock Value
1
NVCT icon
Nuvectis Pharma
NVCT
+$4.41M
2
TBLT
ToughBuilt Industries, Inc. Common Stock
TBLT
+$2.28M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$1.92M
4
BGXX
Bright Green Corporation Common Stock
BGXX
+$1.49M
5
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$1.34M

Sector Composition

Rank Sector Weight
1 Healthcare 9.81%
2 Technology 3.12%
3 Consumer Discretionary 2.1%
4 Communication Services 1.53%
5 Materials 1.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZVRA icon
126
PUT
Zevra Therapeutics
ZVRA
$577M
– –
-896
Closed -$411K
MTVA
127
MetaVia Inc
MTVA
$7.54M
– –
-9,566
Closed -$604K
BGXX
128
DELISTED
Bright Green Corporation Common Stock
BGXX
– –
-1,861,827
Closed -$1.49M
ASLN
129
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-8,768
Closed -$126K
AWH
130
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
– –
-39,873
Closed -$199K
TBLT
131
DELISTED
ToughBuilt Industries, Inc. Common Stock
TBLT
– –
-14,975
Closed -$2.28M
NMTR
132
CALL
DELISTED
9 Meters Biopharma
NMTR
– –
-543
Closed -$68.4K
TRKA
133
DELISTED
Troika Media Group, Inc. Common Stock
TRKA
– –
-66,580
Closed -$193K
AGRX
134
DELISTED
Agile Therapeutics
AGRX
– –
-1,000
Closed -$11.3K
KRBP
135
DELISTED
Kiromic BioPharma, Inc. Common Stock
KRBP
– –
-18,331
Closed -$99.4K
AVCT
136
DELISTED
American Virtual Cloud Technologies, Inc. Common Stock
AVCT
– –
-1,100,000
Closed -$1.26M
BIOR
137
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
– –
-396
Closed -$13K
EQOS
138
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
– –
-23,854
Closed -$642
TMBR
139
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-12,994
Closed -$22.7K
MKD
140
DELISTED
Molecular Data Inc. American Depositary Shares
MKD
– –
-240,745
Closed -$482
RIBT
141
DELISTED
RiceBran Technologies
RIBT
– –
-284,798
Closed -$212K
2 3 4 5
6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2023 Portfolio in Review

As of Q1 2023, Sabby Management held 142 positions worth $115M, up 0.69% from $114M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Sabby Management deployed $6.43M of net new capital in Q1 2023, opening 32 new positions and adding to 15 existing holdings. Its largest new stake was Recon Technology: 219,315 shares worth $1.35M.

By sector, the portfolio is most concentrated in Healthcare at 9.8% of assets, down from 16% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Cocrystal Pharma, an estimated $792K trimmed.

  • Sabby Management's largest Q1 2023 buy was Recon Technology: 219,315 shares worth $1.35M.
  • Sabby Management added most to Akari Therapeutics in Q1 2023, an estimated $1.68M increase.
  • Sabby Management's biggest Q1 2023 reduction was Cocrystal Pharma, cutting an estimated $792K.
  • Sabby Management fully exited Nuvectis Pharma in Q1 2023, selling an estimated $4.41M.
  • Sabby Management's ten largest holdings make up 83% of its $115M portfolio in Q1 2023.
  • Sabby Management opened 32 new positions and closed 53 in Q1 2023.
  • Sabby Management's portfolio value rose 0.69% quarter-over-quarter to $115M.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.